Literature DB >> 35170309

Virus-like Particle Display of Vibrio cholerae O-Specific Polysaccharide as a Potential Vaccine against Cholera.

Zahra Rashidijahanabad1,2, Meagan Kelly3, Mohammad Kamruzzaman4, Firdausi Qadri4, Taufiqur R Bhuiyan4, Hunter McFall-Boegeman1,2, Di Wu5, Grzegorz Piszczek5, Peng Xu6, Edward T Ryan3,7,8, Xuefei Huang1,2,9.   

Abstract

Vibrio cholerae, a noninvasive mucosal pathogen, is endemic in more than 50 countries. Oral cholera vaccines, based on killed whole-cell strains of Vibrio cholerae, can provide significant protection in adults and children for 2-5 years. However, they have relatively limited direct protection in young children. To overcome current challenges, in this study, a potential conjugate vaccine was developed by linking O-specific polysaccharide (OSP) antigen purified from V. cholerae O1 El Tor Inaba strain PIC018 with Qβ virus-like particles efficiently via squarate chemistry. The Qβ-OSP conjugate was characterized with mass photometry (MP) on the whole particle level. Pertinent immunologic display of OSP was confirmed by immunoreactivity of the conjugate with convalescent phase samples from humans with cholera. Mouse immunization with the Qβ-OSP conjugate showed that the construct generated prominent and long-lasting IgG antibody responses against OSP, and the resulting antibodies could recognize the native lipopolysaccharide from Vibrio cholerae O1 Inaba. This was the first time that Qβ was conjugated with a bacterial polysaccharide for vaccine development, broadening the scope of this powerful carrier.

Entities:  

Keywords:  O-specific polysaccharide; Vibrio cholera; bacteriophage Qβ; mass photometry; vaccine

Mesh:

Substances:

Year:  2022        PMID: 35170309      PMCID: PMC9119010          DOI: 10.1021/acsinfecdis.1c00585

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.578


  46 in total

1.  Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.

Authors:  Xuanjun Wu; Zhaojun Yin; Craig McKay; Christian Pett; Jin Yu; Manuel Schorlemer; Trevor Gohl; Suttipun Sungsuwan; Sherif Ramadan; Claire Baniel; Anthony Allmon; Rupali Das; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  J Am Chem Soc       Date:  2018-11-19       Impact factor: 15.419

2.  Quantitative mass imaging of single biological macromolecules.

Authors:  Gavin Young; Nikolas Hundt; Daniel Cole; Adam Fineberg; Joanna Andrecka; Andrew Tyler; Anna Olerinyova; Ayla Ansari; Erik G Marklund; Miranda P Collier; Shane A Chandler; Olga Tkachenko; Joel Allen; Max Crispin; Neil Billington; Yasuharu Takagi; James R Sellers; Cédric Eichmann; Philipp Selenko; Lukas Frey; Roland Riek; Martin R Galpin; Weston B Struwe; Justin L P Benesch; Philipp Kukura
Journal:  Science       Date:  2018-04-27       Impact factor: 47.728

3.  Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

Authors:  Amit Saha; Mohiul Islam Chowdhury; Farhana Khanam; Md Saruar Bhuiyan; Fahima Chowdhury; Ashraful Islam Khan; Iqbal Ansary Khan; John Clemens; Mohammad Ali; Alejandro Cravioto; Firdausi Qadri
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

4.  Synthesis of glycocluster-containing conjugates for a vaccine against cholera.

Authors:  Hélène B Pfister; Meagan Kelly; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Org Biomol Chem       Date:  2019-04-17       Impact factor: 3.876

5.  Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.

Authors:  Zhaojun Yin; Sudipa Chowdhury; Craig McKay; Claire Baniel; W Shea Wright; Philip Bentley; Katarzyna Kaczanowska; Jeffrey C Gildersleeve; M G Finn; Lbachir BenMohamed; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2015-08-11       Impact factor: 5.100

6.  A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.

Authors:  Md Abu Sayeed; Meagan Kelly Bufano; Peng Xu; Grace Eckhoff; Richelle C Charles; Mohammad Murshid Alam; Tania Sultana; Md Rasheduzzaman Rashu; Amanda Berger; Geoffrey Gonzalez-Escobedo; Anjali Mandlik; Taufiqur Rahman Bhuiyan; Daniel T Leung; Regina C LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2015-07-08

7.  Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh.

Authors:  Amena Aktar; M Arifur Rahman; Sadia Afrin; Aklima Akter; Taher Uddin; Tahirah Yasmin; Md Israk Nur Sami; Pinki Dash; Sultana Rownok Jahan; Fahima Chowdhury; Ashraful I Khan; Regina C LaRocque; Richelle C Charles; Taufiqur Rahman Bhuiyan; Anjali Mandlik; Meagan Kelly; Pavol Kováč; Peng Xu; Stephen B Calderwood; Jason B Harris; Firdausi Qadri; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2018-04-23

8.  Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.

Authors:  Bassel Akache; Risini D Weeratna; Aparna Deora; Jennifer M Thorn; Brian Champion; James R Merson; Heather L Davis; Michael J McCluskie
Journal:  Vaccines (Basel)       Date:  2016-01-21

9.  Cholera: Immunity and Prospects in Vaccine Development.

Authors:  Jason B Harris
Journal:  J Infect Dis       Date:  2018-10-15       Impact factor: 5.226

10.  A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A.

Authors:  Jacopo Enotarpi; Marta Tontini; Cristiana Balocchi; Daan van der Es; Ludovic Auberger; Evita Balducci; Filippo Carboni; Daniela Proietti; Daniele Casini; Dmitri V Filippov; Hermen S Overkleeft; Gijsbert A van der Marel; Cinzia Colombo; Maria Rosaria Romano; Francesco Berti; Paolo Costantino; Jeroen D C Codeé; Luigi Lay; Roberto Adamo
Journal:  Nat Commun       Date:  2020-09-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.